KOSDAQBiotech & Pharma060590

CTC Bio

₩2,700 0.00%2026-11-18 close
Market Cap
₩65.3B
Turnover
₩79,848,505
Volume
30K
Shares out.
24.2M
PER
7.2×
PBR
0.8×
EPS
₩372
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

CTC BIO: Checking Quarterly Earnings After the Turnaround

CTC BIO returned to operating profit in 2025, but quarterly operating profit peaked at KRW 4.6 billion in 1Q 2026 and has declined for two straight quarters since, making sustainability the next test.

  1. 1

    Operating profit for 2025 was KRW 6.25 billion, a turnaround from the operating loss in 2024. Of 2022 to 2025, the largest sales year was 2022 at KRW 165.2 billion.

  2. 2

    1Q 2026 posted sales of KRW 34.4 billion and operating profit of KRW 4.6 billion, the peak quarter; operating profit then fell to KRW 3.79 billion in 2Q and KRW 3.14 billion in 3Q, two straight quarterly declines.

  3. 3

    According to MediPana News, the human pharmaceuticals segment reached KRW 84.1 billion in 2024 consolidated sales, or 58.2% of the total, indicating a shift in the business mix away from animal health products.

  4. 4

    Daily Pharm has reported that animal health sales, at KRW 75.2 billion in 2022, have been declining since, so how quickly export contracts show up in earnings remains the key question.

  5. 5

    Over the last four quarters (4Q 2025 to 3Q 2026), net income attributable to controlling shareholders totaled KRW 8.86 billion, and the debt-to-equity ratio fell from 120.8% in 2024 to 97.0% in 2025.

02

Business structure

CTC BIO is a bio and pharmaceutical company built around three segments: animal health, human pharmaceuticals, and raw materials. The animal health segment covers feed additives, disinfectants and vaccines, and the enzyme product CTC-Zyme holds FDA approval and has been the subject of export contracts.

Daily Pharm reported that animal health sales, which reached KRW 75.2 billion in 2022, have declined every year since.

The human pharmaceuticals segment includes improved new drugs, generics and health functional foods; according to MediPana News, it generated KRW 84.1 billion of 2024 consolidated sales, or 58.2% of the total.

The lead product, a combination treatment for premature ejaculation marketed as Wantujeong, received domestic approval in May 2025 and launched in July of the same year, and the company said its Phase 3 results were published in an international journal.

The raw materials business supplies BASF's Kollidon excipient line to domestic pharmaceutical companies with technical support; at seminars in September and October 2026 the company introduced the new excipient SSF and said it plans to expand supply.

Overseas, the company joined the SIAVS 2026 exhibition in Brazil in August 2026 and is discussing product supply and local registration with Latin American feed companies. In 2025 the company said it sold off non-core subsidiaries to concentrate on pharmaceuticals and animal health.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩22.6B₩1.6B6.9%
2025Q4₩31.6B₩1.5B4.8%
2026Q1₩34.4B₩4.6B13.4%
2026Q2₩33.7B₩3.8B11.3%
2026Q3₩31.3B₩3.1B10.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩165.2B₩11.7B₩6.8B7.1%7.0%95.8%
2023₩137.9B-₩4.6B-₩15.6B−3.3%−20.7%119.8%
2024₩144.4B-₩4B-₩5.2B−2.7%−7.5%120.8%
2025₩123.8B₩6.2B₩3.2B5.0%4.5%97.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a reported basis, annual sales went from KRW 165.2 billion in 2022 to KRW 137.9 billion in 2023 (down 16.5% year on year), KRW 144.4 billion in 2024 (up 4.7%), and KRW 123.8 billion in 2025 (down 14.3%). Among 2022 to 2025, 2022 was the largest sales year and 2025 the smallest.

Operating profit swung from KRW 11.7 billion in 2022 to an operating loss of KRW 4.58 billion in 2023, and the company remained in an operating loss of KRW 3.95 billion in 2024, with a smaller deficit.

In 2025 operating profit was KRW 6.25 billion, a return to profit, and the operating margin was 7.1% in 2022, -3.3% in 2023, -2.7% in 2024 and 5.0% in 2025.

Net income attributable to controlling shareholders was KRW 6.75 billion in 2022, a net loss of KRW 15.6 billion in 2023 and KRW 5.22 billion in 2024, then KRW 3.24 billion in 2025, a return to profit.

Net income including non-controlling interests, which differs from the controlling-shareholder figure, was KRW 6.04 billion in 2022, a net loss of KRW 15.6 billion in 2023, a net loss of KRW 5.22 billion in 2024 and net income of KRW 3.24 billion in 2025.

The company attributed the 2025 turnaround to cost efficiency and the divestment of non-core subsidiaries.

By quarter, 3Q 2025 sales were KRW 22.6 billion with operating profit of KRW 1.56 billion; 4Q 2025 sales rose to KRW 31.6 billion (up 39.7% from the prior quarter) with operating profit of KRW 1.51 billion. 1Q 2026 sales were KRW 34.4 billion and operating profit KRW 4.6 billion, up 205.3% from the prior quarter. 2Q 2026 sales were KRW 33.7 billion and operating profit KRW 3.79 billion, and 3Q 2026 sales were KRW 31.3 billion (up 38.1% year on year) with operating profit of KRW 3.14 billion.

Operating profit has fallen for two straight quarters since 1Q 2026. At end-2025, total equity was KRW 72.7 billion, all attributable to controlling shareholders, and total liabilities were KRW 70.5 billion; operating cash flow fell from KRW 18.2 billion in 2022 to KRW 4.38 billion in 2025.

Because the profit recovery came while sales were shrinking, whether the business has moved toward profitability rather than volume is the point to track in later quarters.

05

Industry analysis

Unlike drug developers centered on new drugs such as Hanmi Pharm and Yuhan, CTC BIO combines improved new drugs, pharmaceutical raw materials and animal health products. The company said its R&D strategy emphasizes improved new drugs, which can reach the market faster than novel drugs that require high clinical costs.

Daily Pharm has reported that animal health sales, which stood at KRW 75.2 billion in 2022, have declined each year since, pointing to weakness in both domestic and export demand.

In feed additives, bacteriophage technology has drawn interest alongside the global push to reduce antibiotic use, and the company said local manufacturers remained keen on its offerings at SIAVS 2026 in August 2026.

In raw materials, the company expects demand for binders and disintegrants to rise as pharmaceutical makers tighten quality control standards; this is the company's own assessment, so actual order growth needs to be confirmed in future quarterly sales mix.

Compared with peers, CTC BIO's distinction is holding animal health and raw materials alongside pharmaceuticals, and its market approach differs from large novel-drug developers.

06

Outlook

In its 2025 results announcement, the company described 2025 as a year of restructuring and 2026 as the first year of tangible growth.

In its 2026 half-year announcement, it said it would expand sales of high value-added products in the second half and focus on new export countries and distributors using the network gained at overseas trade fairs. The company expects results from overseas business to become visible gradually from the second half.

It plans to launch the new excipient SSF domestically and expand supply to pharmaceutical makers seeking improved tablet manufacturing processes.

In animal health, it has outlined plans to develop immunity-boosting feed additives aimed at foot-and-mouth disease and avian influenza prevention, along with an upgraded bacteriophage product.

The company said it will expand partnerships with overseas partners and pursue global entry for Wantujeong, based on its Phase 3 results. The timing and scale at which these plans will show up in reported earnings have not yet been disclosed.

With operating profit declining for two straight quarters since 1Q 2026, whether overseas progress feeds into sales from 4Q 2026 onward is the point to confirm.

07

Valuation

PER
7.2×
PBR
0.8×
ROE
11.6%
EPS
₩372
BPS
₩3,370
Dividend per share
₩0

The share price should be read against a history of losses followed by only a short run of profits. Because the company posted net losses attributable to controlling shareholders in 2023 and 2024, a price-to-earnings comparison over that period has no meaningful value.

Over the last four quarters (4Q 2025 to 3Q 2026), net income attributable to controlling shareholders totaled KRW 8.86 billion. On a book-value basis, the share price sits at a relatively low premium to net assets attributable to controlling shareholders.

Market capitalization is below total equity of KRW 72.7 billion at the end of 2025, so the stock trades below its book value. Dividends are effectively absent, which limits valuation comparisons based on dividend yield.

Over several years the earnings direction moved from losses in 2023 to profit in 2025, but because operating profit is small, multiples can swing widely with earnings changes. Given the short profit track record, whether quarterly profits hold is the precondition for reading the multiple.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Profit recovery and a return to profitability

Operating profit in 2025 was KRW 6.25 billion, a turnaround to profit, and 1Q 2026 operating profit of KRW 4.6 billion was the highest quarterly figure in the period. Operating profit stayed positive in every quarter through 3Q 2026.

Net income attributable to controlling shareholders over the last four quarters totaled KRW 8.86 billion, a sharp change from the losses of 2023 and 2024. The operating margin moved from -2.7% in 2024 to 5.0% in 2025.

Growth in in-house products and raw-material demand

The company said it raised the share of higher-margin in-house products over trading items, improving both sales and profitability. Wantujeong received approval in May 2025, launched in July 2025, and its Phase 3 results were published in an international journal.

In raw materials, the company expects demand for binders and disintegrants to rise as pharmaceutical quality standards tighten. The planned domestic launch of the new excipient SSF could broaden that business.

Efforts to enter overseas markets

The company said it attended SIAVS 2026 in Brazil in August 2026 and discussed product supply and local registration with feed companies and feed additive makers. It reported continuing interest from local firms in its beta-mannanase and bacteriophage technologies.

The company expects overseas results to become visible gradually from 2H 2026. Whether this translates into sales will need to be confirmed in later quarterly results.

09

Bear factors

Long-running weakness in animal health

Daily Pharm reported that animal health sales have fallen each year from KRW 75.2 billion in 2022. Although supply contracts for the enzyme product CTC-Zyme have continued, reports of falling export sales have raised doubts about how quickly those contracts convert into revenue.

Annual sales fell from KRW 165.2 billion in 2022 to KRW 123.8 billion in 2025, so the decline in animal health has weighed heavily on the overall top line.

Turn in the direction of quarterly profit

Operating profit peaked at KRW 4.6 billion in 1Q 2026 and then fell to KRW 3.79 billion in 2Q and KRW 3.14 billion in 3Q, two straight quarterly declines. Net income attributable to controlling shareholders was KRW 1.66 billion in 3Q, lower than in 2Q.

The company attributes much of the 2025 turnaround to divesting non-core subsidiaries and cost efficiency, so the underlying profit level after those effects is what needs to be confirmed.

Thinner financial cushion and weaker cash flow

Operating cash flow dropped from KRW 18.2 billion in 2022 to KRW 4.38 billion in 2025. The debt-to-equity ratio fell to 97.0% at end-2025, but total liabilities of KRW 70.5 billion remain close to total equity of KRW 72.7 billion.

Net income attributable to controlling shareholders over the last four quarters totaled KRW 8.86 billion, which is small relative to the equity base, so changes in earnings weigh heavily on returns.

10

Risk factors

Concentration risk

Results are sensitive to swings in both animal health and human pharmaceuticals, and reports indicate that animal health suffered weakness in both domestic and export sales. The timing at which export contracts are reflected in reported results is uncertain, widening the range of sales outcomes.

If results depend on a few products and overseas customers, changes in those relationships could show up in earnings quickly.

Earnings durability risk

The 2025 turnaround was attributed to divesting non-core subsidiaries and cost efficiency, factors that may not repeat at the same scale. Operating profit has declined for two straight quarters since 1Q 2026, and whether the post-peak trend persists is not yet clear. Quarterly results have a short track record of profitability, which increases the sensitivity of later figures.

Regulatory and overseas approval risk

Overseas entry for Wantujeong depends on local approval and clinical data requirements, so timing can vary by market. Animal health exports and Latin American registrations also depend on partner-country regulation, and delayed registration could postpone the recognition of contracted sales. The raw materials business is affected by changes in pharmaceutical quality standards.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report, which will show full-year 2026 sales and operating profit and the 4Q 2026 quarterly figures, confirming how the decline after the 1Q 2026 peak appears in annual results.

  2. Mid-May 2027

    1Q 2027 quarterly report, which will show whether quarterly operating profit stabilizes or recovers and whether the human pharmaceuticals share and animal health sales trends hold.

  3. Date to be announced by the company

    Announcement of the domestic launch of the new excipient SSF and expanded Kollidon supply, showing whether raw-material revenue grows and whether demand rises as pharmaceutical quality standards tighten.

  4. Date to be announced (on contract disclosure)

    Disclosure of supply and local registration agreements with Latin American feed companies, or overseas partnership deals for Wantujeong, to check whether overseas progress reaches sales as the company expects.

12

Overall view

CTC BIO returned to operating profit in 2025 with KRW 6.25 billion, and net income attributable to controlling shareholders turned to KRW 3.24 billion from a loss in 2024. 1Q 2026 operating profit of KRW 4.6 billion was the quarterly peak, but operating profit has fallen for two straight quarters, so the durability of the recovery is not yet confirmed.

The business mix is shifting from animal health toward human pharmaceuticals, while reports indicate animal health sales have declined since 2022.

Overseas entry for Wantujeong, the domestic launch of SSF and expansion in Latin America are areas the company has described as expected growth drivers, but the timing of their impact on reported results is not yet disclosed. The debt-to-equity ratio fell to 97.0% at end-2025, while operating cash flow declined.

The next checkpoints are the 2026 annual report and the 1Q 2027 quarterly report, which will show whether quarterly operating profit stops declining and whether overseas contracts begin to show up in sales.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. medipana.com
  2. newspim.com
  3. kmpnews.co.kr
  4. newstown.co.kr
  5. medipana.com
  6. m.dailypharm.com
  7. dailypharm.com
  8. hitnews.co.kr
  9. comp.fnguide.com
  10. m.news.nate.com
  11. thebionews.net
  12. newspim.com
  13. edaily.co.kr
  14. newspim.com
  15. newspim.com
  16. newspim.com
  17. markets.hankyung.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis